Circulating Tumor DNA (cTDNA) Based in NGS (Next Generation Sequencing) Assays for Oncology Patients With Solid Tumors

Overview

About this study

The purpose of this study is to design, develop and assess the performance characteristics of NGS assays using circulating tumor DNA for the detection of mutations associated solid tumors.

The performance characteristics of these assays for detecting ctDNA mutation in oncology patients will be assessed by comparing the mutation results obtained from these assays to those obtained by orthogonal methods, including tissue-based assays and results from a ctDNA assay by Guardant on blood.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients seen in Oncology or surgery with a diagnosis of a solid tumor malignancy,.

Exclusion Criteria:

< 18 years of age.

Eligibility last updated 7/28/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Gang Zheng, M.D., Ph.D.	Open for enrollment	Contact information: Helayna Sjoberg (507) 293-9690 Sjoberg.Helayna@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Gang Zheng, M.D., Ph.D.

Open for enrollment

Contact information:

Helayna Sjoberg

(507) 293-9690

Sjoberg.Helayna@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials